I expect that a fair proportion of patients who have not progressed in 24 months will continue to take Keytruda, if reimbursement is not an issue.
This FDA approval, which was not in doubt, comes two months before the 12/24/16 PDUFA date. The timing is perfect insofar as MRK reports 3Q16 results tomorrow.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.